Diminished ovarian reserve in Behcet's disease patients

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author MONT'ALVERNE, Andrea R. S. FMUSP-HC
YAMAKAMI, Lucas Y. S. FMUSP-HC
GONCALVES, Celio R. FMUSP-HC
BARACAT, Edmund C. FMUSP-HC
BONFA, Eloisa FMUSP-HC
SILVA, Clovis A. FMUSP-HC
dc.date.issued 2015
dc.identifier.citation CLINICAL RHEUMATOLOGY, v.34, n.1, p.179-183, 2015
dc.identifier.issn 0770-3198
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/9414
dc.description.abstract This study aims to assess ovarian reserve markers in Beh double dagger et's disease (BD) patients. Ten BD and 22 healthy controls were evaluated for ovarian reserve by examining the levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, inhibin B, total morning testosterone, prolactin, thyroid-stimulating hormone (TSH), and antral follicle count. Anti-Mullerian hormone (AMH) was measured using two different enzyme-linked immunosorbent assay (ELISA) kits. Demographic data, menstrual abnormalities, disease parameters, and treatments were also analyzed. The median current age was similar in BD patients and controls (34 (20-40) vs. 31.3 (20-42) years, p = 0.33). A positive correlation was observed between the AMH Gen II ELISA and AMH/MISAnshLabs ELISA assays in the BD patients (r = +0.98; p < 0.0001) and healthy controls (r = +0.93; p < 0.0001). The mean AMH by Gen II (0.93 +/- 0.8 vs. 2.59 +/- 1.8 ng/mL, p = 0.01) and AMH/MIS AnshLabs ELISA (1.07 +/- 0.86 vs. 2.51 +/- 1.8 ng/mL, p = 0.02) were significantly reduced in the BD patients versus controls. A trend of decreased AMH (< 1.0 ng/mL) was observed in BD patients compared to that in the controls (50 vs. 19 %, p = 0.09) using either kits. The mean FSH was significantly higher in the BD patients compared to that in the controls (9.1 +/- 3.6 vs. 6.5 +/- 2.7, p = 0.04). No differences were found for the other ovarian parameters in both groups (p > 0.05). Current disease activity was only observed in BD patients with a low AMH level; however, there was no statistical significance (40 vs. 0 %, p = 0.44). Cyclophosphamide use was reported in only one patient with a low AMH and high FSH level. The present study was the first to suggest that BD patients may have diminished ovarian reserve. The contribution of disease activity remains to be determined.
dc.language.iso eng
dc.publisher SPRINGER LONDON LTD
dc.relation.ispartof Clinical Rheumatology
dc.rights restrictedAccess
dc.subject Anti-Mullerian hormone; Antral follicle count; Behcet's disease; Fertility
dc.subject.other systemic-lupus-erythematosus; juvenile dermatomyositis; hormonal alterations; rheumatic-diseases; gonadal-function; adolescents; fertility; women
dc.title Diminished ovarian reserve in Behcet's disease patients
dc.type article
dc.rights.holder Copyright SPRINGER LONDON LTD
dc.description.group LIM/17
dc.description.group LIM/36
dc.description.group LIM/58
dc.identifier.doi 10.1007/s10067-014-2680-5
dc.identifier.pmid 24878927
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author MONT'ALVERNE, Andrea R. S.:FM:
hcfmusp.author YAMAKAMI, Lucas Y. S.:FM:
hcfmusp.author GONCALVES, Celio R.:HC:ICHC
hcfmusp.author BARACAT, Edmund C.:FM:MOG
hcfmusp.author BONFA, Eloisa:FM:MCM
hcfmusp.author SILVA, Clovis A.:FM:MPE
hcfmusp.origem.id WOS:000347160600025
hcfmusp.origem.id 2-s2.0-84930677486
hcfmusp.publisher.city LONDON
hcfmusp.publisher.country ENGLAND
hcfmusp.relation.reference · Aikawa NE, 2001, RHEUMATOL INT, V31, P1097
· Aikawa NE, 2010, CLIN EXP RHEUMATOL, V28, P571
· Aikawa NE, 2012, CLIN EXP RHEUMATOL, V30, P445
· Bleil ME, 2014, FERTIL STERIL, V101, P199, DOI 10.1016/j.fertnstert.2013.09.015
· Cil AP, 2010, DIAGN INTERV RADIOL, V16, P288, DOI 10.4261/1305-3825.DIR.3049-09.1
· Clark CA, 2014, HUM REPROD, V29, P184, DOI 10.1093/humrep/det413
· Criteria for diagnosis of Behcet's disease, 1990, LANCET, V335, P1078
· Freour T, 2008, REPROD BIOMED ONLINE, V16, P96
· Hendriks DJ, 2007, FERTIL STERIL, V87, P764, DOI 10.1016/j.fertnstert.2006.11.006
· Medeiros PB, 2009, LUPUS, V18, P38, DOI 10.1177/0961203308094652
· Moraes AJP, 2008, BRAZ J MED BIOL RES, V41, P1142, DOI 10.1590/S0100-879X2008001200016
· Moraes AJP, 2010, CLIN EXP RHEUMATOL, V28, P441
· Neves FS, 2007, CLIN RHEUMATOL, V26, P1263, DOI 10.1007/s10067-006-0484-y
· Ostensen M, 2011, RHEUMATOLOGY, V50, P657, DOI 10.1093/rheumatology/keq350
· Practice Committee of the American Society of Reproductive Medicine, 2012, FERTIL STERIL, V98, P1407
· Satwik Ruma, 2012, J Hum Reprod Sci, V5, P206, DOI 10.4103/0974-1208.101023
· Seifer DB, 2009, FERTIL STERIL, V92, P1674, DOI 10.1016/j.fertnstert.2008.08.110
· Silva CA, 2014, AUTOIMMUN REV, V13, P427, DOI 10.1016/j.autrev.2014.01.003
· Silva CA, 2012, CLIN REV ALLERG IMMU, V42, P256, DOI 10.1007/s12016-011-8281-z
· Silva CA, 2010, ARTHRIT CARE RES, V62, P1682, DOI 10.1002/acr.20323
· Silva CAA, 2002, J RHEUMATOL, V29, P2000
· Silva CAA, 2002, LUPUS, V11, P419, DOI 10.1191/0961203302lu219oa
· Silva CAA, 2007, LUPUS, V16, P531, DOI 10.1177/0961203307079300
· Silva CAA, 2007, LUPUS, V16, P593, DOI 10.1177/096120330707077538
· Soares PMF, 2007, ARTHRITIS RHEUM, V56, P2352, DOI 10.1002/art.22660
· Suehiro RM, 2008, RHEUMATOLOGY, V47, P1692, DOI 10.1093/rheumatology/ken338
· Uzunaslan D, 2014, RHEUMATOLOGY, V53, P828, DOI 10.1093/rheumatology/ket436
dc.description.index MEDLINE
dc.identifier.eissn 1434-9949
hcfmusp.citation.scopus 16
hcfmusp.citation.wos 18


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics